NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell lines by Tsofack, Serges P et al.
RESEARCH Open Access
NONO and RALY proteins are required for YB-1
oxaliplatin induced resistance in colon
adenocarcinoma cell lines
Serges P Tsofack
1,2, Chantal Garand
1, Chris Sereduk
3, Donald Chow
3, Meraj Aziz
3, David Guay
4, Hongwei H Yin
3
and Michel Lebel
1,2*
Abstract
Background: YB-1 is a multifunctional protein that affects transcription, splicing, and translation. Overexpression of
YB-1 in breast cancers causes cisplatin resistance. Recent data have shown that YB-1 is also overexpress in
colorectal cancer. In this study, we tested the hypothesis that YB-1 also confers oxaliplatin resistance in colorectal
adenocarcinomas.
Results: We show for the first time that transfection of YB-1 cDNA confers oxaliplatin resistance in two colorectal
cancer cell lines (SW480 and HT29 cell lines). Furthermore, we identified by mass spectrometry analyses important
YB-1 interactors required for such oxaliplatin resistance in these colorectal cancer cell lines. A tagged YB-1
construct was used to identify proteins interacting directly to YB-1 in such cells. We then focused on proteins that
are potentially involved in colorectal cancer progression based on the Oncomine microarray database. Genes
encoding for these YB-1 interactors were also examined in the public NCBI comparative genomic hybridization
database to determine whether these genes are localized to regions of chromosomes rearranged in colorectal
cancer tissues. From these analyses, we obtained a list of proteins interacting with YB-1 and potentially involved in
oxaliplatin resistance. Oxaliplatin dose response curves of SW480 and HT29 colorectal cancer cell lines transfected
with several siRNAs corresponding to each of these YB-1 interactors were obtained to identify proteins significantly
affecting oxaliplatin sensitivity upon gene silencing. Only the depletion of either NONO or RALY sensitized both
colorectal cancer cell lines to oxaliplatin. Furthermore, depletion of NONO or RALY sensitized otherwise oxaliplatin
resistant overexpressing YB-1 SW480 or HT29 cells.
Conclusion: These results suggest knocking down NONO or RALY significant counteracts oxaliplatin resistance in
colorectal cancers overexpressing the YB-1 protein.
Background
Colorectal cancer is the third leading cause of cancer-
related death in the Western world (National Cancer
Institute; 2009). Over 50% of those diagnosed require
systemic therapy at some point during the disease tra-
jectory. Clinical resistance is almost inevitable for
advanced colorectal cancer within 6-12 months of any
given therapy. For example, clinical responses of meta-
static cancers (e.g. death and elimination of cancer cells)
to the most advanced therapeutic agents range from 15
to 40%, indicating intrinsic resistance in a majority of
colorectal cancer tissues [1]. In addition, acquired resis-
tance almost inevitably occurs in tumors that initially
responded [1]. One of the most effective regimens
against colorectal cancers, either in adjuvant or in meta-
static settings, is the combination of fluoropirimidine
and oxaliplatin. Oxaliplatin is a third generation plati-
num analogue that kills cells by forming adducts on
DNA, the most prevalent of which is intra-strand link-
age of two adjacent guanines [2]. Nevertheless, the
majority of patients with colon cancer are either intrin-
sically resistant to this drug or become resistant during
therapy. Oxaliplatin-resistant cells are characterized by
decreased DNA adduct formation [3]. The exact
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any medium, provided the original work is properly cited.mechanisms responsible for this resistance are still elu-
sive to this date.
Several studies have indicated that the overexpression
of YB-1 (Y box-binding protein-1) is related with sec-
ondary resistance to cisplatin in melanomas, breast,
ovarian, and bladder cancers [4-7]. Furthermore, deple-
tion of YB-1 expression protein with anti-sense RNA
against YB-1 specific mRNA results in increased sensi-
tivity to cisplatin [8]. Interestingly, YB-1 is increased in
cultured cell lines resistant to cisplatin. In fact, several
studies have indicated that the level of nuclear expres-
sion of YB-1 is predictive of drug resistance and patient
outcome in breast tumors, ovarian cancers, and synovial
sarcomas [5,7,9-11]. YB-1 preferentially binds to cispla-
tin-modified DNA [12]. Further analyzes have indicated
that YB-1 actively promotes strand separation of duplex
DNA containing either mismatches or cisplatin modifi-
cations independently of the nucleotide sequence [13] in
addition to having an exonuclease activity [14]. YB-1
was originally described as a transcription regulator that
binds to inverted CCAAT box DNA sequences present
in the control regions of several genes [15]. In addition
to the regulation of transcription, YB-1 is a multifunc-
tional protein that also affects the splicing and the trans-
lation of specific mRNAs [16-18]. Several mRNAs
regulated by YB-1 are potentially important for che-
moresistance [18].
It has been reported that YB-1 expression is increased
in colorectal carcinomas compared to normal colon tis-
sues [19]. Although overexpression of YB-1 confers cis-
platin resistance in breast and ovarian cancers, it is
unknown whether increase YB-1 expression would also
confer oxaliplatin resistance in colorectal cancers [20].
In this study, we investigated the impact of YB-1 on
oxaliplatin resistance in two different colon adenocarci-
noma cell lines. We show that overexpression of YB-1
confers oxaliplatin resistance and a depletion of YB-1
sensitizes cells to oxaliplatin treatments in culture. In
addition, we identified by mass spectrometry analyses
important YB-1 interactors required for such oxaliplatin
resistance in these colorectal cancer cell lines. Knock
down analyses of two of these proteins, NONO and
RALY, increased oxaliplatin sensitivity in otherwise
resistant colorectal cancer cells overexpressing YB-1.
Methods
Cell lines and drugs
The human HT29 colon adenocarcinoma cell line was
obtained from the American Type Culture Collection
(ATCC) and maintained in McCoy’s 5A media supple-
mented with 2 mM L-Glutamine, 10% Fetal Bovine
Serum (FBS), and 1% Antibiotic-Antimytotic (Invitrogen,
Carlsbad, CA) at 37°C in atmosphere of 5% CO2.T h e
human SW480 colon adenocarcinoma cell line (also
obtained from ATCC) was maintained in RPMI supple-
mented with 10% Fetal Bovine Serum (FBS), and 1%
Antibiotic-Antimytotic (Invitrogen, Carlsbad, CA) at 37°
C in atmosphere of 5% CO2. Oxaliplatin was purchased
from the Hôtel-Dieu Hospital in Quebec City (Qc,
Canada).
Antibodies
A polyclonal antibody against the N-terminus portion of
YB-1 (ab12148) was purchased from Abcam, Inc. (Cam-
bridge, MA). The mouse monoclonal antibody against
HNRPB2A1 (sc-32316) and a rabbit polyclonal antibody
against HNRPL (sc-28726) were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). The mouse poly-
clonal antibody against RALY (H00138046-B030), a
mouse polyclonal antibody against MRPL13
(H00028998-B01), and a goat polyclonal antibody
against NONO (PAB 7027) were purchased from
Abnova Corp. (Taipei City, Taiwan). A rabbit polyclonal
antibody against RIBC2 (HPA003210) was purchased
f r o mS i g m a - A l d r i c hI n c .( S t - L o u i s ,M O ) .F i n a l l y ,a l l
horseradish peroxidase-conjugated secondary antibodies
(anti-rabbit IgG: NAV934V and anti-mouse IgG:
NA931V) were purchased from GE Healthcare Limited
(Piscataway, NJ). The above antibodies were used as
indicated by the manufacturers. Western blotting ana-
lyses were performed as described [13].
Plasmids and transfections
The YB-1 cDNA was cloned in the pNTAP-B vector in-
frame with the TAP-epitope consisting of both calmo-
dulin and streptavidin epitopes (Stratagene, LaJolla, CA).
SW480 cells were transfected with Effectene (Qiagen,
Inc., Mississauga, ON) and selected in 600 μg/ml of
neomycin (Invitrogen, Carlsbad, CA) for two weeks.
Colonies were expended and analyzed by Western blot-
ting with an antibody against YB-1 to select TAP-YB-1
expressing clones. The pCMV-YB-1 construct was
described before [13]. This YB-1 expression vector was
transfected into SW480 cells with the Amaxa nucleofec-
tor kit V as described by the manufacturer (Lonza Com-
pany, Basel, Switzerland). A transfection efficiency of
19.8% in SW480 cells was routinely obtained with a
fluorescent GFP-YB-1 construct using this transfection
protocol (data not shown).
Tandem affinity purification and mass spectrometry
analyses
The TAP-YB-1 protein was purified from a stable
SW480 clone expressing this protein construct with a
TAP purification kit (Stratagene, LaJolla, CA) as
described by the manufacturer. We also used large
amounts of RNAse A (100 μg/mL) in our extraction
buffers to eliminate contaminating ribonucleic acids that
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complexes. SW480 cells containing an empty TAP vec-
tor were used as a control. Eluted proteins were ana-
lyzed by SDS-PAGE and lanes corresponding to control
TAP and TAP-YB-1 expressing cells were cut into small
gel slices. Gel slices were sent to the Proteomics plat-
form of the Quebec Genomic Center (Quebec City, Qc,
Canada) for spectrometry analyses and protein identifi-
cations. Briefly, gel slices were disposed into 96-well
plates and in-gel trypsin digestion was performed on a
MassPrep™ liquid handling station (Waters, Missis-
sauga, ON) according to the manufacturer’s specifica-
tions. Peptide extracts were dried out using a
SpeedVac™. Peptide extracts were separated by online
reversed-phase nanoscale capillary LC and analyzed by
electrospray MS (ES MS/MS). The experiments were
performed on a Thermo Surveyor MS pump connected
to a LTQ linear ion trap mass spectrometer (Thermo
Electron, San Jose, CA) equipped with a nanoelectros-
pray ion source (Thermo Electron, San Jose, CA). Pep-
tide separation took place within a PicoFrit column
BioBasic C18, 10 cm × 0.075 mm internal diameter
(New Objective, Woburn, MA) with a linear gradient
from 2% to 50% solvent B (acetonitrile, 0.1% formic
acid) in 30 min, at 200 nl/min. Mass spectra were
acquired using data-dependent acquisition mode (Xcali-
bure software, version 2.0). Each full-scan mass spec-
trum (400-2000 m/z) was followed by collision-induced
dissociation of the seven most intense ions. The
dynamic exclusion function was enabled (30 s exclu-
sion), and the relative collisional fragmentation energy
was set to 35%.
All MS/MS samples were analyzed using Mascot
(Matrix Science, London, UK; version 2.2.0). Mascot was
set up to search against human Uniref_100 protein data-
base assuming a digestion with trypsin. Fragment and par-
ent ion mass tolerance were, respectively, of 0.5 Da and
2.0 Da. Iodoacetamide derivative of cysteine was specified
as a fixed modification. Deamidation of asparagine and
glutamine, acetylation of lysine and arginine and oxidation
of methionine were specified as variable modifications.
Scaffold (version 01_07_00; Proteome Software Inc., Port-
land, OR) was used to validate MS/MS-based peptide and
protein identifications. Peptide identifications were
accepted if they could be established at > 95.0% probability
as specified by the Peptide Prophet algorithm [21]. Protein
probabilities were assigned by the Protein Prophet algo-
rithm [22]. Proteins that contained similar peptides and
could not be differentiated based on MS/MS analysis
alone were grouped to satisfy the principles of parsimony.
Using these stringent identification parameters, the rate of
false positive identifications is < 1%.
To confirm protein interactions, TAP-YB-1 protein
complexes were purified from a stable SW480 clone
expressing the TAP-YB-1 construct with a TAP purifi-
cation kit (Stratagene, LaJolla, CA) as described by the
manufacturer. SW480 cells containing an empty TAP
vector were used as a control. Eluted proteins were ana-
lyzed by SDS-PAGE followed by Western blotting with
the appropriate antibodies.
Oncomine analyses
Oncomine is a cancer microarray database and web-
based data-mining platform aimed at facilitating discov-
ery from genome-wide expression analyses. Data can be
queried and visualized for a selected gene across micro-
array analyses available to the public. The parameter for
the research in Oncomine included as primary filters
the official name of the gene (or protein interacting with
YB-1) and the analysis type, which was colorectal cancer
versus normal tissue analysis. The threshold used to
obtain the most significant probes of the queried gene
for each microarray data included a two-fold difference
in expression between cancers and normal tissues with a
P-value < 1 × 10
-4.
siRNA screening
The antisense technology has been described as a poten-
tial anti-cancer therapy for the treatment of several clin-
ical cancers and several molecules are in phase I and II
trials [23]. In general, cells were reverse-transfected with
a custom arrayed set of 18 genes (4 siRNA sequences/
gene) using RNAiMax (Invitrogen, Carlsbad, CA) for
SW480 cells or DharmaFect 3 (Dharmacon, Lafayette,
CO) for HT29 cells and incubated at 37°C for 24 hours
followed by treatment with various concentrations of
oxaliplatin and incubated for an additional 96 hours
before measuring cell viability via the CellTiter-Glo
l u m i n e s c e n ta s s a yk i ta c c ording to the manufacturer’s
protocol (Promega, Madison, WI). All scramble siRNA
controls (GFP, ASNS, and NS) as well as the positive
transfection control (Allstar Cell Death Control or
ACDC) were purchased from Qiagen (Valencia, CA).
One microliter of 0.667 μM siRNA was printed into
bar-coded 384 well solid-white bottom plates (Corning
8749, Lowell, MA) using a Biomek FX Laboratory Auto-
mation Workstation for a final assay concentration of
13 nM per well. siRNA buffer [100 mM Potassium
Acetate, 30 mM HEPES-KOH, 2 mM Magnesium Acet-
a t e( p H7 . 6 ) ]w a sp r i n t e di n t ot h ef i r s tt w oc o l u m n so f
the plate to serve as a control. A transfection reagent
solution of RNAiMax and serum free RPMI was added
to the plates using a BIO-TEK μFill Microplate Dispen-
ser at 20 μl per well (40 nl RNAiMax/well). The plates
containing siRNA and transfection reagents were incu-
bated at room temperature for 30 minutes prior to add-
ing cells to allow complexes to form. Cells were
trypsinized, counted, resuspended in 10% FBS assay
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20 μl per well for SW480 cells using the BIO-TEK μFill
Microplate Dispenser for a final FBS concentration of
5% (20 μl serum free + 20 μl 10% FBS media). Plates
were incubated at 37°C for 24 hours prior to dosing
them with 10 μl/well of varying concentrations of oxali-
platin diluted in 5% FBS assay media using a μFill. Initi-
ally, twelve different drug concentrations, together with
vehicle control, were applied for each control siRNA to
obtain a drug dose response curve. Subsequently, six
concentrations of oxaliplatin [200, 66.7, 22.2, 7.4, 2.47,
0.82, and 0 μM] spanning the entire response range of
the drug were applied to SW480 cells during the siRNA
screening process. The first column of every plate (con-
taining siRNA buffer, no siRNA) was left untreated to
serve as a control for plate-to-plate variation. Plates
were incubated for an additional 96 hours post drug
treatment and then read for cell viability. The screen in
SW480 cells was performed in two independent runs.
siRNAs altering SW480 sensitivity to oxaliplatin were
also tested in HT29 cells. Identical protocols were used
for these cells, with the following exceptions: Dharma-
FECT 3 was delivered at a concentration of 200 nl/well
and six concentrations of oxaliplatin [250, 100, 40, 16,
6.4, 2.56, and 0 μM] spanning the entire dose response
range of HT29 cells were used for the siRNA screening
process based on an initial test with twelve different
oxaliplatin concentrations.
The siRNA sequences against YB-1 are 5’-AAGAA-
GAAAUAUGAAAUUCCA-3’ for sequence siRNA-A, 5’-
CUGCAAGCACCUGUUAAUAAA-3’ for siRNA-B, and
5’-CAGGCGAAGGUUCCCACCUUA-3’ for siRNA-C.
Growth curves and FACS analyses
For growth curves, 10 to 50 thousands cells were plated
in 60 mm dishes (or 35 mm dishes when indicated) and
counted with a hemacytometer by the trypan blue exclu-
sion technique every other day. For FACS analyses, tryp-
sinized cells were collected and centrifuged on a top
bench centrifuge for 2 min. Cell were resuspended in
PBS and an equal volume of 95% cold ethanol was
added. The next day cells were centrifuged and the pel-
let was resuspended in a propidium iodide buffer (0.1%
citrate; 0.3% NP-40; 0.002 mg/ml of RNAse A; 50 μg/ml
propidium iodide at pH 7.4). Cells were incubated 30
min at 37°C and then analyzed on a Coulter
® Epics XL-
MCL™ Flow Cytometer (Beckman Coulter Canada, Inc.,
Mississauga, ON). Data were analyzed with the Multi-
Cycle software (Phoenix Flow System, San Diego, CA,
USA).
RT-PCR
The primers used to amplify a 116 base pairs fragment
of the HPRT1 (hypoxanthine phosphoribosyltransferase
1) cDNA are HPRTRev 5’-GCACACAGAGGGCTA-
CAATG-3’ and HPRTFor 5’-TGAGGATTTGGAAAG
GGTGT-3’. The primers used to amplify a 527 base
pairs fragment of the YB-1 cDNA are Y159For 5’-
CCAGCAAAATTACCAGAAT-3’ and UNYB1Rev 5’-
TGATGGTAGAGATGGTAAGC-3’. Reverse transcrip-
tase was performed on 300 ng of total RNA with either
the HPRTRev or the UNYB1Rev primer. The cDNA was
then amplified with Taq DNA polymerase and the
appropriate forward primers for each target mRNA. The
PCR conditions for the HPRT1 cDNA were 1 min at
94°C, 1 min at 55°C, and 1 min at 72°C for 30 cycles.
The PCR conditions for the YB-1 cDNA were 1 min at
94°C, 1 min at 58°C, and 1 min at 72°C for 30 cycles.
Amplified products were analyzed on a 2% agarose gel.
Results
Overexpression of YB-1 in SW480 colon cancer cells
induce oxaliplatin resistance
We first tested the impact of oxaliplatin on SW480 sur-
vival. Cells were treated with oxaliplatin for 24, 48 or 72
hours and live cells were counted with trypan blue on a
hemacytometer (Figure 1A). SW480 cells were more
sensitive after a 48-hour oxaliplatin treatment than only
after a 24-hour treatment. Wet h e nt r a n s f e c t e dS W 4 8 0
colorectal cancer cells with the full-length wild type YB-
1 construct or an empty expression vector as a control.
Six hours later, transfected cells were treated with oxali-
platin for 24 or 48 hours before counting the cells by
the trypan blue exclusion assay with a hemacytometer.
As indicated in Figure 1B, YB-1 overexpression induced
a two-fold increase in cell survival in the presence of
one or two μM oxaliplatin concentrations over the
transfected control empty expression vector. The differ-
ence between YB-1 and control transfected cells were
more evident with a 24-hour oxaliplatin treatment (Fig-
ure 1B). We determined whether the transfection proto-
col had an impact on endogenous YB-1 expression in
SW480 cells. YB-1 protein levels in cells transfected
with a control empty vector was equivalent to endogen-
ous YB-1 levels in nontransfected cells (Figure 1C). We
also performed clonogenic assays to measure overall cell
survival after oxaliplatin treatment. Briefly, transfected
cells were treated 18 hours with different concentrations
of oxaliplatin and then re-plated in fresh media without
oxaliplatin for 10 days to allow colony formation. Non-
transfected cells were also included as an additional
negative control experiment. Clonogenic assays indi-
cated a three-fold difference in the number of colonies
at 1.5 μM oxaliplatin between YB-1 overexpressing
SW480 cells and transfected or nontransfected control
cells (Figure 1D). YB-1 protein levels were on average
1.8-fold higher in YB-1 transfected SW480 cells com-
pared to cells transfected with an empty vector (Figure
Tsofack et al. Molecular Cancer 2011, 10:145
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increases oxaliplatin resistance in SW480 cells.
Identification of YB-1 partners in SW480 colon cancer
cells
The expression of YB-1 in colorectal cancer was queried
i nt h eO n c o m i n ep u b l i cd a t a b a s e[ 2 4 ] .O n c o m i n ei sa
cancer microarray database and web-based data-mining
platform aimed at facilitating discovery from genome-
wide expression analyses. Data can be queried and
visualized for a selected gene across all microarray ana-
lyses available to the public. A number of microarray
studies have indicated a significant increase in YB-1
expression in colon cancer tissues compared to normal
colon tissues [25-27]. In addition, a search of the litera-
ture indicated that YB-1 was overexpressed in almost all
cancerous lesions in comparison with normal mucosa in
surgically resected colorectal carcinomas of 26 patients
Figure 1 Impact of YB-1 overexpression on oxaliplatin resistance in SW480 cells. A) Survival assay of SW480 cells treated for 24, 48, or 72
hours with the indicated concentrations of oxaliplatin. Live cells were then counted with a hemacytometer by the trypan blue exclusion
technique. Experiments were performed in duplicate. Bars represent SEM. B) Survival assays of SW480 cells transfected with either wild type YB-1
or an expression empty vector. Six hours after the transfections, cells were treated with one or two μM of oxaliplatin for 24 or 48 hours. Live
cells were then counted with a hemacytometer by the trypan blue exclusion technique. Experiments were performed in duplicate. Bars
represent SEM. C) Example of Western blots showing endogenous YB-1 expression in control transfected cells (6 hours after transfection) and in
nontransfected SW480 cells. The histogram below the Western blots represents the YB-1 signal over b-actin signal. D) Clonogenic assays with
SW480 cells transfected either with wild type YB-1 or an empty expression vector. Transfected cells were treated (6 hours after transfection) with
the indicated concentrations of oxaliplatin for 18 hours and then plated in 90-mm petri dishes with fresh media without drugs for 10 days.
Survival fraction represents the number of colonies after treatment divided by the number of colonies without treatment (in %). Results
represent the mean ± SEM of duplicate experiments. E) Example of Western blots showing YB-1 expression in transfected cells (6 hours after
transfection). Bands were revealed using an ECL plus kit after less than a five second exposition. The histogram below the Western blots
represents the YB-1 signal over b-actin signal.
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size that YB-1 overexpression may play a role in color-
ectal cancers. Moreover, it is possible that YB-1 confers
oxaliplatin resistance in the context of a protein com-
plex in colon cells. To identify YB-1 protein partners
that may also affect oxaliplatin resistance, the YB-1
cDNA was cloned in frame with a TAP tag containing a
calmodulin and a streptavidin binding peptide for Tan-
dem Affinity Purification. Such construct was trans-
fected into the SW480 colon cancer cell line. Several
stable viable clones were obtained (Figure 2A shows an
example of one such clone). The expression level of
total YB-1 (endogenous plus TAP-YB-1) was 1.7-fold
higher than in SW480 clones expressing the TAP con-
struct alone. The SW480 clones expressing the TAP-
YB-1 construct were more resistant to oxaliplatin than
cells expressing the TAP control alone (Figure 2B and
2C show an example of one such clone). Thus, stable
SW480 clones expressing the TAP-YB-1 behaved like
SW480 transiently transfected with a YB-1 expression
vector (Figure 1). We next characterized the growth rate
of TAP-YB-1 expressing SW480 cells, which are more
resistant to oxaliplatin than TAP expressing cells. Figure
3 indicates that TAP-YB-1 expressing SW480 cells had
a slower growth rate than TAP expressing SW480 cells
(estimated doubling time of 29 and 38 hours for TAP
and TAP-YB-1, respectively). TAP-YB-1 expressing
SW480 cells tended to accumulate in the G2/M phases
of the cell cycle (Figure 3B) compared to TAP expres-
sing cells (Figure 3C and 3D). These results are consis-
tent with previous observation indicating that YB-1
overexpression affects mitosis [28,29].
Co-purification of proteins was achieved on exponen-
tially growing SW480 cells expressing either the TAP
alone or the TAP-YB-1 construct. RNAse A was used in
the extraction buffer to avoid isolating YB-1 protein
complex bound to RNA molecules. Unbound proteins at
each step of the chromatography process were removed
by extensive washing thus obtaining proteins stringently
bound to the TAP-YB-1 construct in cell lysates. Bound
proteins were identified by liquid chromatography tan-
dem mass spectrometry (LC MS/MS). The experiment
was repeated nine times. Proteins identified from both
SW480 TAP and TAP-YB-1 expressing cells were con-
sidered artifacts and removed from the final list of
potential YB-1 interacting proteins. Additional file 1
gives a list of potential proteins interacting with the
TAP-YB-1 construct in SW480 cells. Based on all the
identified peptides, there are 128 proteins (excluding
YB-1 itself) that potentially can interact with the TAP-
YB-1 construct in SW480 cells. Only 67 proteins, how-
ever, were identified by more than two peptides in all
nine experiments (Additional file 1) with high confi-
dence. We thus continued our analysis on proteins that
were identified by at least two peptides in our mass
spectrometry data.
We next confirmed the interaction of six of these pro-
teins picked randomly from our list (Additional file 1)
by Western blotting analyses (Figure 2D). Total cell
lysate from TAP-YB-1 and TAP SW480 clones were
incubated with streptavidin binding resin overnight in a
cold room and proteins were eluted the next day for
immunoblot analyses with antibodies against
HNRPA2B1, HNRPL, MRPL13, NONO, RALY, and
RIBC2. As indicated in Figure 2D, all these proteins
bound the TAP-YB-1 construct but not the TAP con-
struct alone.
Identification of YB-1 interactants differentially expressed
in colon cancer
To determine whether YB-1 interactants were poten-
tially relevant in colon cancer, we searched for their pre-
sence in the Oncomine public database [24]. We
queried each YB-1 interacting encoding gene product
for their expression levels in colon cancer compared to
normal colon tissues. In addition, we determined
whether each gene was localized (using the UCSC gen-
ome browser at http://genome.ucsc.edu/) to region of
the genome rearranged in colon cancer using the com-
parative genomic hybridization (CGH) database from
the NCBI web site http://www.ncbi.nlm.nih.gov/pro-
jects/sky/. This database contains 163 colon cancer
cases analyzed by the CGH methods (by October 2011).
Table 1 indicates the localization of the genes encoding
each YB-1 interacting protein and the number of cases,
which demonstrated amplification or deletion of the
genomic region containing these genes. Overall, 24
genes coding for potential YB-1 interactants were ampli-
fied and overexpressed or deleted and underexpressed
in colon cancers (Table 1). In addition, based on the lit-
erature, five of these genes (RPS7, PABPC1, RPS4X,
HNRNPL, and RALY) were up regulated in oxaliplatin
resistant ovarian cell lines [30] (Table 1). The other
genes did not show significant changes in their expres-
sion in colon cancer and were not further considered in
this study.
Identification of YB-1 interactants affecting oxaliplatin
resistance by the anti-sense technology
To identify YB-1 partners directly involved in oxaliplatin
resistance, a high throughput screening with four differ-
ent small interference RNAs for each target gene (from
Table 1) was applied to SW480 cells followed by an ana-
lyses in HT29 cells. Two different cell lines were used to
determine the reproducibility of our assays in colon ade-
nocarcinoma cells established from different patients.
We first evaluated the sensitivity of SW480 and HT29
cells to the drug oxaliplatin by determining their EC50
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Page 6 of 18Figure 2 Increased oxaliplatin resistance in SW480 cells expressing the TAP-YB-1 construct and validation of TAP-YB-1 interaction
with six identified protein from the LC-MS/MS. A) Representative Western blot analysis of SW480 clones expressing the TAP or the TAP-YB-1
constructs. b-actin was used as loading controls. The histogram below the Western blots indicates the endogenous and TAP-YB-1 expression
levels in the indicated clones. B) Survival assays of SW480 clones expressing TAP or TAP-YB-1 constructs. Cells were treated with one or two μM
of oxaliplatin for 18 h. Live cells were then counted with a hemacytometer by the trypan blue exclusion technique. Experiments were performed
in duplicate. Bars represent SEM. C) Clonogenic assays with SW480 clones expressing TAP or TAP-YB-1 constructs. Cells were treated with the
indicated concentrations of oxaliplatin for 18 hours and then plated in 90-mm petri dishes with fresh media without drugs for 10 days. Survival
fraction represents the number of colonies after treatment divided by the number of colonies without treatment (in %). Results represent the
mean ± SEM of duplicate experiments. D) TAP-YB-1 interaction of HNRPA2B1, HNRPL, MRPL13, NONO, RALY, and RIBC2 with the YB-1 protein.
Proteins from TAP and TAP-YB-1 expressing SW480 cells were eluted from the streptavidin beads and analyzed by SDS-PAGE with antibodies
against the indicated proteins. Proteins were revealed with an ECL Plus kit. WCE represents the whole cell lysate. TAP represents the protein
eluted from the streptavidin beads.
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oxaliplatin treatment than HT29 cells. The EC50 value
for SW480 and HT29 was 7 μMa n d5 2μM, respec-
tively (Figure 4A and 4B). We then tested whether the
transfection protocols used in this study had any effect
on drug sensitivity. We achieved a very high transfection
efficiency (> 90% of transfection efficiency) using the
RNAiMAX transfection reagents for the SW480 cell line
and the DharmaFect 3 transfection reagents for the
HT19 cell line (data not shown). Initially, twelve differ-
ent drug concentrations, together with vehicle control,
were applied for each siRNA to obtain a drug dose
response curve. As shown in Figure 4A, the transfection
of a control siRNA against the Green Fluorescent Pro-
tein (GFP) in SW480 did not significantly affect oxali-
platin sensitivity compared to nontransfected SW480
cells. In contrast, the transfection protocol used to
obtain > 90% transfection efficiency in HT29 cells signif-
icantly increased oxaliplatin sensitivity in this cell line
(Figure 4B). Nevertheless, as indicated in Figure 4A and
4B, cells transfected with the different siRNA controls
(GFP, NS, ASNS) behaved consistently for both cell
lines (EC50 ranging from 3.6-5.1 μM and 18.1-21.4 μM
for SW480 and HT29 cells, respectively). We thus used
siRNA against GFP as a control reference for our siRNA
screening experiments and six different oxalipatin
Figure 3 Cell growth of SW480 cells expressing TAP and TAP-YB-1 constructs. A) Growth curves of TAP and TAP-YB-1 expressing SW480
clones. B) Graph representing the percentage of the various TAP construct expressing cells in each phase of the cell cycle. C) Example of cell
cycle by FACS analyses with SW480 cells expressing a TAP construct. D) Example of cell cycle by FACS analyses with SW480 cells expressing the
TAP-YB-1 construct.
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dose response curves of each cell line as indicated in the
materials and methods section and the Additional file 2.
Under these conditions, SW480 cells were still more
sensitive to oxaliplatin treatments than HT29 cells.
In our first round of screening experiment, we focused
our study on genes localized to chromosome amplifica-
tions and which are overexpressed in colon cancers
based on public databases. Based on the availability of
sets of siRNA molecules (e.g.f o u ru n i q u es i R N A
sequences per target), we knocked down 18 targets in
SW480 cells and first measure their effects on cell viabi-
lity (using the CellTiter-Glo luminescent assay) in the
absence of oxaliplatin. We eliminated targets that
showed cell viability < 50% upon siRNA knockdown in
the absence of oxaliplatin (Additional file 3). From this
first analysis, there were five sets of siRNAs (represent-
ing 27% of the siRNAs screened) demonstrating cyto-
toxicity > 50% even in the absence of oxaliplatin. We
next determined the sensitivity of the remaining 13 tar-
gets to oxaliplatin (using siRNA against GFP as a con-
trol reference) upon transfection with siRNAs against
their corresponding mRNA. To eliminate the risk of off-
target effects of a specific siRNA sequence, we
prioritized targets that had at least two different siRNA
sequences specific to their corresponding mRNA
demonstrating the same effect in the presence of oxali-
platin. We identified from this siRNA screen eight pro-
teins of interest that had an impact on cell viability in
SW480 cells treated with oxaliplatin upon depletion
(data not shown).
In our second round of siRNA screening experiment,
we retested these eight genes (including negative con-
trols) in the presence of various oxaliplatin concentra-
tions from duplicated experiments for both the SW480
and HT29 colon cancer cell lines. The impact of each
siRNA on the EC50 value for oxaliplatin compared to
control transfected SW480 or HT29 cells is summar-
ized in Table 2. The depletion of only two proteins,
NONO and RALY, lead to a greater sensitivity to oxa-
liplatin in both colon adenocarcinoma cell lines with at
least two siRNA sequence molecules. Figure 5 shows
examples of normalized response of transfected SW480
and HT29 cells to specific oxaliplatin concentrations
and the calculated EC50 values for each siRNA target-
ing NONO or RALY. Based on the EC50 values, three
siRNA molecules against NONO (siRNA a, c, and d)
sensitized both SW480 and HT29 cells to the drug
Table 1 List of potential YB-1 partners with their chromosomal location and expression levels in colon cancer
CGH databases
(163 colon cancer cases)
ONCOMINE databases Oxaliplatin
Protein name Accession number Chromosome cases amplification deletion comments resistance
C1QBP Q07021 17p13.3 44 8 36 down with grade and recurrence -
FBRL P22087 19q13.2 26 25 1 up in tumor vs normal -
RPS7 P62081 2p25.3 28 26 2 up in tumor vs normal up
CHCHD9 Q5T1J5 9q21.31 22 19 3 up in tumor vs normal -
HNRPK P61978 9q21.32 22 19 3 up in tumor vs normal -
MRPL19 P49406 2p12 22 22 0 up with grade -
PABPC1 P11940 8q22.3 62 61 1 up in tumor vs normal up
MRPL9 Q9BYD2 1q21.3 24 23 1 up in tumor vs normal -
MRPS7 Q9Y2R9 19p13.12 30 25 5 up with genetic instability -
PTCD3 Q96EY7 2p11.2 25 25 0 up in tumor vs normal -
SYNCRIP O60506 6q14.3 31 26 5 up in tumor vs normal -
MRPL43 A8K4V4 10q24.31 19 14 5 up with genetic instability -
SERPINH1 A8K259 11q13.5 28 26 2 up in tumor vs normal -
RPS4X P62701 Xq13.1 46 41 5 up in tumor vs normal up
MRPL44 Q9H9J2 2q36.1 25 23 2 up with genetic instability -
ILF2 Q12905 1q21.3 24 23 1 up in tumor vs normal -
NONO A8K525 Xq13.1 46 41 5 up in tumor vs normal -
HNRNPL A6ND69 19q13.2 24 23 1 up with genetic instability up
LOC138046 O60812 8q21.2 59 58 1 up in tumor vs normal -
MRPS27 Q92552 5q13.2 23 9 14 up with genetic instability -
RALY A8K4T9 20q11.22 92 92 0 up in tumor vs normal up
MRPL23 A6NGQ5 11p15.5 27 26 1 up in tumor vs normal -
MBL2 P11226 10q21.1 16 14 2 up in metastasis vs colon primary tumor -
MRPS14 O60783 1q25.1 25 24 1 up in tumor vs normal -
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5A and 5B). Two siRNA molecules against RALY
(siRNA a and c) sensitized both SW480 and HT29
cells to the drug oxaliplatin by more than 42% (sum-
marized in Figure 5C and 5D). Figure 4C and 4D show
the results as the ratio of EC50 for each siRNA
sequence over the EC50 value for the control siRNA
against GFP. The siRNAs against the other YB-1 inter-
actants that had little effect or opposite effects on oxa-
liplatin sensitivity in SW480 and HT29 cells were not
considered further in this study (effects summarized in
Table 2).
Validation of NONO and RALY depletions by Western
blots
Based on our results, several siRNAs against NONO
and RALY consistently increased oxaliplatin sensitivity
in both colon adenocarcinoma (SW480 and HT29) cell
lines. We first determined the efficiency of the knock
down of these specific siRNA sequences by Western
blotting in both cell lines. As shown in Figure 6,
siRNA sequence a, c, and d against NONO mRNA sig-
nificantly decreased NONO protein levels in both
SW480 and HT29 cells. These siRNA sequences sensi-
t i z e dS W 4 8 0a n dH T 2 9c e l l sto oxaliplatin by at least
25% (Figure 5A and 5B) and is consistent with a signif-
icant depletion of NONO in the transfected cells (Fig-
ure 6A and 6B). Two siRNA sequences against RALY
mRNA (siRNA a and c) consistently, decreased RALY
protein levels in both SW480 and HT29 cells. These
molecules sensitized SW480 and HT29 cells to oxali-
platin (Figure 5C and 5D) and this result is consistent
with a significant depletion of RALY in both cell lines
(Figure 6C and 6D). The depletion of NONO or RALY
protein correlated with oxaliplatin sensitivity in each
cell line (Figures 4 and 6).
We examined the growth rate of SW480 cells trans-
fected with a scrambled control siRNA or siRNA
sequence against NONO (siNONOa) or RALY (siRA-
LYc). As indicated in Figure 7A, the knock down of
either RALY or NONO was still efficient four days after
the transfection. Nevertheless, the difference in cell
growth between transfected cells was not statistically sig-
nificant (Figure 7B). FACS analyses also indicated no dif-
ference in the percentage of cells in each cycle of the cell
cycle between siControl, siNONO, and siRALY trans-
fected cells (data not shown). These results indicate that
the increased oxaliplatin sensitivity in siNONO or
siRALY transfected cells was not due to changes in the
rate of cell growth.
Figure 4 Graphs showing the changes in oxaliplatin EC50 for each siRNA sequence against controls, NONO, and RALY compared to
the oxaliplatin EC50 of cells transfected with a control siRNA against GFP. A) Oxaliplatin dose response curves obtained with different
control siRNAs in SW480 cells. B) Oxaliplatin dose response curves obtained with different control siRNAs in SW480 cells. No tfx indicates no
transfection. Mock tfx indicates transfection without a siRNA molecule. NS and All-Star NS (ASNS) are nonspecific siRNA sequences. GFP indicates
siRNA against Green Fluorescent Protein. ACDC stands for Allstar Cell Death Control. The ratio (EC50 of the indicated siRNA over the EC50 of
transfected siRNA against GFP) is shown for C) SW480 and D) HT29 transfected cells. EC50 values were calculated from the oxaliplatin dose
response curves obtained after transfection of the individual siRNA sequence a, b, c, and d targeting the indicated protein. Experiments were
performed in duplicate.
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and HT29 cells
Since a knock down of NONO and RALY increased oxali-
platin sensitivity, we compared the levels of these proteins
in the untransfected SW480 and HT29 cells. As men-
tioned earlier, SW480 cells are more sensitive to oxalipla-
tin than HT29 cells. Figure 8A and 8B show that the
protein levels of NONO and RALY were 70%-80% higher
in the more oxaliplatin resistant HT29 cells than the
SW480 cells. YB-1 protein levels were 16% higher in
HT29 than in SW480 cells. These results indicate a corre-
lation between NONO and RALY expression and oxalipla-
tin resistance in HT29 and SW480 colorectal cancer cells.
Finally, we estimated the growth rate of parental cells in
culture (Figure 8C). The estimated doubling time for
HT29 and SW480 cells was 29 and 35 hours, respectively.
Co-regulation of YB-1 and NONO in SW480 cells
We next examined the impact of knocking down
NONO and RALY protein levels on YB-1 expression in
the parental SW480 cells. Cells were transfected with
either a scrambled control siRNA or siRNA sequence
against NONO (siNONOa) or RALY (siRALYc) and 96
hours later lysates were extracted for Western blot ana-
lyses. As shown in Figure 8D and 8E, siRNA sequence
against RALY decreased YB-1 protein levels in SW480
cells by 34%. Knocking down NONO decreased YB-1
protein levels by 50%. Knocking down NONO or RALY
with siNONOb or siRALYa molecules also decreased
YB-1 protein levels in cells (Additional file 4). In con-
trast, NONO knock down had no significant effect on
RALY expression and RALY knock down had no effect
on NONO expression (Figure 8D). Interestingly, a
Table 2 Summary of the impact of siRNAs to deplete eight proteins in SW480 and HT29 colorectal cancer cell lines
treated with oxaliplatin (compared to EC50 of siRNA against GFP).
Gene Name siRNA Sequence of siRNA Phenotype in SW480 Phenotype in HT29
FBL a CCGGAUGGUCUAGUCUAUGCA Resistance Sensitivity
b CCUCAUUAACUUGGCCAAGAA No change Sensitivity
c UUCAUUUGUCGAGGAAAGGAA Resistance Sensitivity
d CUGCGUAAUGGAGGACACUUU Resistance Sensitivity
FLJ20758 a ACCAUUUAGAUUCAACAUUAA Resistance Sensitivity
b CAGGACAGAGAGAGUAAAUUA Resistance Sensitivity
c AACCAGUUAGCUGCUAUAUAA Resistance Sensitivity
d CCCAGGAAAUAGCCUAUUAAA No change No change
HNRPK a CAGCAAGUUUAUUAAUCAGAA Resistance Sensitivity
b CUCUAGUGUCUUAUUAGUUAA No change Sensitivity
c AUGGAAGUGACUAAUGCUGAA Resistance No change
d UUCCAUUGUAUGCAAAUUGAA No change No change
NONO a CCAAGUGGACCGCAACAUCAA Sensitivity Sensitivity
b CUGUGUUUGAUUUGUCUCAUA No change Sensitivity
c AGGCUUGACUAUUGACCUGAA Sensitivity Sensitivity
d AACAAACGUCGCCGAUACUAA Sensitivity Sensitivity
PABPC1 a AAACGUAAUUUGGAUUAUAAA No change No change
b CGGGCUCGGAACACACAUUUA Resistance Sensitivity
c GACAAAUCCAUUGAUAAUAAA No change No change
d CCGCACCGUUCCACAGUAUAA Resistance Sensitivity
RALY a CUCAGCCAAGAUCAAGUUAAA Sensitivity Sensitivity
b CGGGCAGACCCUGGACAUCAA No change Sensitivity
c AAGCAAUGUAACCAACAAGAA Sensitivity Sensitivity
d CACCAUGUCCUUGAAGCUUCA No change Sensitivity
RPS7 a CCGGCUAGUACGCGAAUUGGA Resistance Resistance
b CACGGGCAAGGAUGUUAAUUU Resistance Resistance
c CAGCCGGCUCAUAAAGGUUCA Resistance Resistance
d UUCGAGCGCCAAGAUCGUGAA Resistance Resistance
RPS8 a UGGCUAUGUGCUAGAGGGCAA Resistance Resistance
b AUCGUGCUCAUCGACAGCACA Resistance Resistance
c CUCAGAGUGUUGUACUCGUAA Resistance Resistance
d AAGAGUUGGAGUUCUAUCUUA Resistance No change
Genes in bold indicate similar effects with at least two siRNA molecules in both cells lines.
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protein in SW480 but it had no impact on RALY pro-
tein levels in SW480 cells (Figure 8F). These results sug-
gest that YB-1 and NONO regulate each other in
SW480 cells.
We next examine whether a depletion of NONO or
RALY also decreased the mRNA transcript level of YB-1
in addition to its protein level. Cells were transfected
with either a scrambled control siRNA or siRNA
sequence against NONO (siNONOa) or RALY (siRA-
LYc) and 96 hours later cytoplasmic RNA were isolated
for RT-PCR analyses with primers specific for YB-1 and
HPRT1 genes. As indicated in Figure 9, a depletion of
NONO decreased the mRNA levels of YB-1 but had no
effect on the mRNA levels of the control HPRT1 gene.
The depletion of RALY had no significant effect on YB-
1 and HPRT1 transcript levels compared to the
scrambled control siRNA transfection. These results
suggest that NONO depletion has an impact on YB-1
expression at the transcriptional stage and a depletion
of RALY has an impact on YB-1 expression at the post-
transcriptional level.
Finally, we examined the impact of knocking down
YB-1 on oxaliplatin sensitivity in parental SW480 cells.
As indicated in Figure 10A and 10B, a depletion of YB-1
in SW480 cells with two different siRNA sequences
increased oxaliplatin sensitivity.
The effect of depleting NONO or RALY in YB-1
overexpressing SW480 and HT29 cells
We next examine the impact of knocking down NONO
or RALY protein levels in oxaliplatin resistant YB-1
overexpressing SW480 and HT29 cells. Cells were first
transfected with the siRNA sequences (siControl, siNO-
NOa, or siRALYc). Three days after this first transfec-
tion, cells were re-transfected with an empty vector or a
vector expressing YB-1. Cells were treated with two μM
of oxaliplatin overnight. The next day cells were
counted with a hemacytometer. Knocking down NONO
or RALY increased sensitivity of cells to two μM of oxa-
liplatin by 25-40% (Figure 10C and 10D) as shown pre-
viously in Figure 5. Transfection of YB-1 expression
vector significantly increased oxaliplatin resistance in
SW480 and HT29 cells compared to an empty
Figure 5 Histograms showing the response of transfected SW480 and HT29 cells to the drug oxaliplatin. SW480 cells were transfected
with four different siRNA sequences against A) NONO and C) RALY. HT29 cells were transfected with four different siRNA sequences against B)
NONO and D) RALY. As controls, cells were transfected with a non-specific siRNA against the green fluorescent protein (GFP). Responses of three
oxaliplatin concentrations (out of eight tested) are shown. EC50 for each transfected siRNA is also indicated.
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Knocking down the expression of NONO or RALY sig-
nificantly sensitized YB-1 overexpressing SW480 and
HT29 cells to oxaliplatin treatments by 1.5- and 4.4-
fold, respectively (Figure 10C and 10D).
Overexpression of YB-1, NONO, and RALY transcripts in
other cancer histotypes
To determine whether YB-1, NONO, and RALY mRNA
transcripts could also be increased in other cancer histo-
types, we searched the PrognoScan database. PrognoS-
can is web-based data-mining platform http://gibk21.bio.
kyutech.ac.jp/PrognoScan/index.html aimed at facilitat-
ing meta-analysis of the prognostic value of genes in dif-
ferent cancers. It provides survival data associated with
microarray analyses. The additional file 5 gives a sum-
mary of the cancer types in which overexpression of
either YB-1, NONO, or RALY are associated with poor
outcome of the diseases. To summarize, overexpression
of YB-1 was associated with poor prognoses in ovarian,
lung, breast, prostate, bladder, head and neck cancers, as
well as in multiple myelomas and melanomas (with cor-
rected or COX P-values < 0.05). Overexpression of
NONO was associated with poor prognoses in lung,
brain, breast cancers, and multiple myelomas. Overex-
pression of RALY was associated with poor survival in
ovarian, lung, bladder, brain, and breast cancers as well
as in multiple myelomas and melanomas. Interestingly,
several studies indicated co-overespression of YB-1 with
NONO and/or RALY (highlighted in the table of Addi-
tional file 5).
Discussion
Oxaliplatin has become an effective first-line therapy for
colorectal cancer. One major problem with oxaliplatin
regimen, however, is the appearance of resistant tumor
cells during the course of the treatment. A second pro-
blem is the lack of knowledge on a common mechanism
that confers oxaliplatin resistance in several colorectal
adenocarcinomas. A number of microarray studies have
indicated a significant incr e a s ei nY B - 1e x p r e s s i o ni n
colon cancer tissues compared to normal colon tissues
[25-27] and one immunohistochemistry study had
reached a similar conclusion [19]. In this study, we
examined whether overexpression of YB-1 could confer
oxaliplatin resistance in two colorectal cancer cell lines.
Transient transfection experiment in SW480 and HT29
colorectal cancer cells and stable SW480 clones overex-
pressing a TAP-YB-1 construct all demonstrated a sig-
nificant resistance to the drug oxaliplatin. From this
information, we then asked whether a specific YB-1 pro-
tein complex is required to confer oxaliplatin resistance
in SW480 and HT29 cells. We first identified by mass
spectrometry analyses proteins binding directly to a
Figure 6 Knock down of NONO and RALY with specific siRNA
molecules in SW480 and HT29 cells. Cells were transfected with
the indicated siRNA molecules and 96 hours later proteins were
extracted for Western blot analyses. SW480 and HT29 cells were
transfected respectively with siRNAs against NONO and RALY.
SiControl represents non-specific siRNA molecules. In every blot, b-
actin was used as loading controls. Graph representing
densitometric analyses of the Western blots are also shown. Bars in
each histogram represent the SEM. Examples of Western blots and
scanning analyses of cells transfected with siRNAs against NONO in
A) SW480 and B) HT29 cells. Examples of Western blots and
scanning analyses of cells transfected with siRNAs against RALY in
C) SW480 and in D) HT29 cells.
Figure 7 Growth rate of RALY and NONO depleted cells.A )
Examples of Western blots showing RALY and NONO expression
four days after the transfections with the siRNA sequences siRALYc
and siNONOa. B) Growth curves of SW480 cells transfected with
siRNA sequences against NONO (siNONOa), RALY (siRALYc), or a
scrambled control siRNA molecule. Transfected cells were plated in
60 mm petri dishes and live cells were counted every other day
with a hemacytometer.
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Page 13 of 18Figure 8 Co-regulation of NONO and YB-1 in SW480 cells. A) Basal expression of YB-1, NONO, and RALY in SW480 and HT29 cells. B)
Histogram representing the relative expression of YB-1, NONO, and RALY in untransfected cells. Error bars represent the standard error of the
mean. C) Growth curves of SW480 and HT29 cells. Cells were plated in 35 mm petri dishes and live cells were counted every other day with a
hemacytometer. D) SW480 cells were transfected with siRNA sequences against NONO (siNONOa) or RALY (siRALYc) and 96 hours later cell
lysates were extracted for Western analyses with antibodies against NONO, RALY, and YB-1. E) Histogram representing the relative expression of
YB-1 in cells transfected with siNONOa or siRALYc. Error bars represent the standard error of the mean. F) SW480 cells were transfected with
three different siRNA sequences against YB-1 and 96 hours later cell lysates were extracted for Western analyses with antibodies against NONO,
RALY and YB-1. In every blot, b-actin was used as loading controls.
Figure 9 Impact of depleting endogenous NONO or RALY proteins on YB-1 transcript levels. A) SW480 cells were transfected with the
indicated siRNA molecules and 96 hours later cytoplasmic RNAs were extracted for RT-PCR analyses with primers specific to the YB-1 and HPRT1
mRNAs. All primers used for the PCR step hybridized to two different exons of the target genes. RT indicates the presence or the absence of the
reverse transcriptase for the cDNA synthesis step. Experiments were performed in duplicates. B) Graph showing YB-1 mRNA expression relative to
the HPRT1 expression in SW480 cells transfected with the indicated siRNA sequences. Bars represent the SEM.
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teins were identified with at least two peptides. To focus
on proteins with the highest physiological relevance to
chemioresistance in colorectal cancer, we opted for an
integrative approach by collecting information on each
protein with regard to gene expression and status
(which includes genetic rearrangements) in colon can-
cers. Based on different public databases, 23 of these
YB-1 partners were overexpressed at the transcriptional
level in colorectal tumors, in metastasis, and associated
with increased genomic instability in colon cancers. The
transcription of one protein was decreased in recurring
colon cancer. These observations indicated that the
transcription levels of such proteins could potentially be
used as prognostic markers. Based on microarray studies
of different cell lines, the proteins HNRPL, PABPC1,
RPS4X, RPS7, and RALY are overexpressed in ovarian
cancer cells resistant to oxaliplatin [30]. From such
information, we determined whether the depletion of
these proteins up regulated in colorectal adenocarcino-
mas (Table 1) have an impact on oxaliplatin sensitivity
on both SW480 and HT29 cancer cells. We used the
knock down technology in this study as siRNA mole-
cules can have potential therapeutic benefits. Impor-
tantly, the antisense technology has been described as a
potential anti-cancer therapy for the treatment of several
clinical cancers and several molecules are in phase I and
II trials [23]. We tested four siRNA sequences for each
target proteins in the list of Table 1. Different siRNA
sequences for the same target often gave inconsistent
results in the two cells lines used in this study (Table 2).
Such results are not surprising as it is now well accepted
that a siRNA sequence may present off-target effects
that may differ depending on the transcriptome of each
cell line [31-33]. We thus focused on proteins which
showed at least two different siRNA sequences against
the mRNAs corresponding to these proteins with the
same phenotype in two different cancer cell lines. Based
on these criteria, we observed that the depletion of
RALY or NONO increased oxaliplatin sensitivity in both
SW480 and HT29 cells. More importantly, the siRNA
Figure 10 Impact of depleting endogenous NONO or RALY
proteins in YB-1 overexpressing SW480 and HT29 oxaliplatin
resistant cells. A) Survival assays of SW480 cells transfected with
either siRNA against YB-1 (siYB-1-b or siYB-1-c) or a nonspecific
control siRNA. Three days after the transfections, cells were treated
with one or two μM of oxaliplatin for 24 h. Live cells were then
counted with a hemacytometer by the trypan blue exclusion
technique. Experiments were performed in duplicate. Bars represent
SEM. B) Example of Western blots showing YB-1 expression in
transfected cells (96 hours after transfection). Bands were revealed
using an ECL plus kit after less than five second of exposition. The
histogram below the Western blots represents the YB-1 signal over
b-actin signal. C) SW480 cells were transfected with the indicated
siRNA sequences specific to NONO (siRNA sequence a), RALY (siRNA
sequence c), or scrambled control siRNA. Forty-eight hours later,
cells were transfected with YB-1 expression vector or empty
expression control vector. Transfected cells were plated in 100 mm-
petri dishes and were then treated with one μM of oxaliplatin for
16 hours in culture before counting live cells. Results represent the
mean ± SEM of quadruplicate experiments. D) HT29 cells were
transfected with the indicated siRNA sequences specific to NONO,
RALY, or scrambled control siRNA. Forty-eight hours later, cells were
transfected with YB-1 expression vector or empty expression control
vector. Transfected cells were plated in 100 mm-petri dishes and
were then treated with two μM of oxaliplatin for 16 hours in culture
before counting live cells. Results represent the mean ± SEM of
triplicate experiments.
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ciently depleted RALY or NONO proteins (Figure 6).
RALY (hnRNP-associated with lethal yellow homolog
(mouse)) is a member of the heterogeneous nuclear
ribonucleoprotein gene family. It is associated with the
spliceosome complex [34]. It is unknown, however,
whether RALY also affects transcription and DNA repair
like YB-1 in cells [15,35,36]. One microarray study
reported an increase of RALY expression in cells resis-
tant to oxaliplatin along with the proteins HNRNPL,
PABPC1, RPS4X, and RPS7 (Table 1) [30]. Our results,
however, indicate that RALY is the only protein that
sensitizes colorectal cancer cells to oxaliplatin when
depleted with siRNAs. It is possible that HNRNPL,
PABPC1, RPS4X, and RPS7 correlate with oxaliplatin
resistance but are not directly involved biochemically in
the process of resistance in colorectal cancer cell types.
We recently found that a depletion of RPS4X increased
cisplatin resistance in YB-1 overexpressing breast cancer
cell lines [37]. We did not observe such cellular
response in colorectal cancer cells upon oxaliplatin
treatment in our study. This maybe due to the intrinsic
difference between breast and colon cancer cell types, or
it could be due to the different manner in which cells
respond to cisplatin and oxaliplatin. For example, it has
recently been reported that gamma irradiation of two
teratoma cell lines in vitro induced resistance to subse-
quent oxaliplatin treatment, but increased sensitivity to
cisplatin [38]. Notably, cisplatin and oxaliplatin DNA
damage are not processed by the same DNA repair sys-
tems [39,40].
NONO (non-POU domain containing, octamer-bind-
ing) gene encodes an RNA-binding protein, which plays
various roles in the nucleus, including transcriptional
regulation and RNA processing [41-44]. A study with a
GFP-NONO has indicated that the protein localizes not
only to the nucleolus but also in nuclear speckles rich
in splicing factors [41]. In addition to mRNA processing,
NONO is involved in the repair of DNA double
stranded breaks [45-47]. It is believed to participate in
both the non-homologous end joining and the homolo-
gous recombination repair pathways with its homologue
SFPQ (splicing factor proline/glutamine-rich). We did
not identify, however, SFPQ in our mass spectrometry
analyses as a protein interacting with the TAP-YB-1
construct.
Messenger RNA processing (which includes splicing)
is a common biological process shared by YB-1, NONO,
and RALY proteins [16,34,41]. Exon-array profiling is
warranted in NONO, RALY, and YB-1 depleted cells to
find common spliced mRNAs affected by these proteins
during oxaliplatin response. Independent of the exact
mechanisms involved in oxaliplatin resistance, NONO
and RALY are good potential targets for the
sensitization of otherwise oxaliplatin resistant YB-1
overexpressing colorectal cancer tumor cells (Figure 10).
Interestingly, NONO or RALY knock down decreased
endogenous YB-1 protein levels. The exact mechanism
by which these proteins regulate YB-1 expression is
unknown but our RT-PCR results indicate that a deple-
tion of NONO also down regulates the level of YB-1
transcripts. In contrast, a depletion of RALY in SW480
cells did not significantly affect YB-1 mRNA levels.
Thus, unlike NONO, RALY regulates the amount of
YB-1 protein in SW480 cells at the post-transcriptional
level. Additional experiments are required to determine
which steps of YB-1 mRNA processing and transport
NONO and RALY are involved in.
Finally, a depletion of YB-1 decreased NONO expres-
sion in SW480 cells but had no effect on RALY expres-
sion. This result is consistent with findings indicating
that the promoter of NONO but not the promoter of
RALY is a target of the YB-1 transcription factor [48]. It
is possible that YB-1 regulates the transcription of the
NONO gene in colorectal cancer cells. Epidemiological
studies on appropriate cohorts of patients with colorec-
tal cancer are warranted to determine whether the
expressions of YB-1, NONO, and RALY have predictive
values for the response to oxaliplatin treatment.
Conclusions
Taken together, our results indicate that overexpression
of YB-1 confers oxaliplatin resistance in colorectal
SW480 and HT29 cancer cells. We show for the first
time that YB-1 interacts with NONO and RALY in the
colorectal cancer cell line SW480. Importantly, the
knock down of either NONO or RALY sensitizes in
otherwise oxaliplatin overexpressing YB-1 SW480 and
HT29 colorectal cancer cell lines. These results suggest
that knocking down NONO or RALY is a potential
therapeutic strategy to counteract oxaliplatin resistance
in colorectal cancers.
Additional material
Additional file 1: Table of the list of proteins identified by mass
spectrometry in TAP-YB-1 eluate. The total number of peptides
identified by LC-MS/MS for each protein is indicated on the right.
Additional file 2: Oxaliplatin dose response curves and EC50 in
SW480 and HT29 cells. A) The graph on the left represents a twelve-
point drug dose response (DDR) obtained with different control siRNAs
in SW480 cells. The graph on the right represents the drug response
curves obtained with the six concentrations used for the siRNA screening
process in SW480 cells. B) The graph on the left represents a twelve-
point drug dose response (DDR) obtained with different control siRNAs
in HT29 cells. The graph on the right represents the drug response
curves obtained with the six concentrations used for the siRNA screening
process in HT29 cells. No tfx indicates no transfection. Mock tfx indicates
transfection without a siRNA molecule. NS and All-Star NS (ASNS) are
nonspecific siRNA sequences. GFP indicates siRNA against Green
Fluorescent Protein. ACDC stands for Allstar Cell death Control. EC50
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Page 16 of 18values were calculated from the oxaliplatin dose response curves
obtained after transfection of the indicated siRNA sequences.
Experiments were performed in duplicate.
Additional file 3: Impact of siRNAs on SW480 colorectal cancer cell
viability. The tables in this file present the raw data on the viability of
SW480 cells after the transfections of siRNA sequences.
Additional file 4: Impact of depleting NONO and RALY proteins on
YB-1 levels in SW480 cells. Examples of Western blots showing YB-1,
NONO, and RALY expression four days after the transfections with the
siRNA sequences A) siNONOa and siNONOb and B) siRALYa and siRALYc
molecules.
Additional file 5: Microarray data showing high expression of YBX1,
NONO, or RALY mRNAs in different sets of cancer patients with
poor outcome of the disease. The table gives a list of microarray data
set showing an association between poor outcomes of cancer patients
with high expression of YB-1, NONO, and/or RALY transcripts. The cancer
type, the probe for each transcript, and the array type used in the
studies are provided with P-values for the association. Highlighted are
studies showing co-expression of the three different genes.
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